Course Description “CDK4/6 Inhibition in Breast Cancer”

This program discusses the history of targeted therapies in breast cancer and the emerging role of CDK4/6 treatments. It gives an overview of the role of the tumor microenvironment and how it impacts treatment response. The content covers the role of targeted therapy in breast cancer and provides a summary of existing clinical evidence. Finally, the program describes combinatorial treatment strategies and their impact on treatment response.

Objectives

Upon completion of this program, clinicians will be able to:

• Explain the epidemiology, pathology, and etiology of HR+ and HER2+ advanced breast cancer

• Discuss endocrine resistance in advanced breast cancer

• Visualize CDK4/6 inhibition pathways in advanced breast cancer

• Understand targeted therapies and sequencing for advanced breast cancer

Target Audience

Oncologists, primary care physicians, and other clinicians who manage patients with breast cancer.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of New York Medical College and the Angiogenesis Foundation. New York Medical College is accredited by the ACCME to provide continuing medical education for physicians.

New York Medical College designates this Enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

All activity faculty and planners participating in continuing medical education activities provided by New York Medical College are expected to disclose to the audience any significant support or substantial relationship(s) with commercial entities whose products are discussed in their presentation and/or with any commercial supporters of the activity. In addition, all faculty is expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentations.

William Li, MD
Chairperson
Dr. Li has nothing to disclose with regard to commercial interests.

Jeffrey McRae, MS
Program Planner
The Angiogenesis Foundation
Mr. McRae has nothing to disclose with regard to commercial interests.

Commercial Support Acknowledgement:

We gratefully acknowledge Eli Lilly for their generous support of this educational activity.

Instructions for Participation and Credit:

There are no fees for participating in or receiving credit for this online educational activity.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit:

• Read the objectives, audience, and disclosure statements
• Review the graphic and text content
• Complete the Course Quiz, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

Release and Expiration
Date of original release: July 15, 2019
Date of expiration: July 14, 2020